Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

Exact Sciences' Q3 earnings report has led to a ~25% drop in its share price, due to a slight guidance cut and narrow revenue miss. Despite impressive historic revenue growth, Exact faces ...

QRG Capital Management Inc. grew its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 13.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The ...

Revenue: US$708.7m (up 13% from 3Q 2023). Net loss: US$38.2m (down from US$794.0k profit in 3Q 2023). US$0.21 loss per share (down from US$0.004 profit in 3Q 2023). Revenue missed analyst ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

A world leading pharmacologist from Papua New Guinea has been elected the first president of the Pacific Academy of Sciences. Professor Teatulohi Matainaho has been involved in researching traditional ...